Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV002513742 | SCV003523516 | pathogenic | Charcot-Marie-Tooth disease type 2 | 2022-07-12 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 33 of the LMNA protein (p.Glu33Gly). This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Glu33 amino acid residue in LMNA. Other variant(s) that disrupt this residue have been observed in individuals with LMNA-related conditions (PMID: 14985400, 17377071), which suggests that this may be a clinically significant amino acid residue. Experimental studies have shown that this missense change affects LMNA function (PMID: 31296869). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 66962). This missense change has been observed in individual(s) with clinical features of autosomal dominant LMNA-related conditions and/or clinical features of dominant LMNA-related conditions (PMID: 16891232, 22491857; Invitae). In at least one individual the variant was observed to be de novo. |
Epithelial Biology; Institute of Medical Biology, |
RCV000057495 | SCV000088609 | not provided | not provided | no assertion provided | not provided |